Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (FRA:08HH)

Germany flag Germany · Delayed Price · Currency is EUR
2.130
+0.106 (5.24%)
At close: Mar 27, 2026
Market Cap8.07B +1.0%
Revenue (ttm)5.07B +1.4%
Net Income410.43M +21.7%
EPS0.15 +22.4%
Shares Outn/a
PE Ratio19.67
Forward PE18.51
Dividend0.04 (1.89%)
Ex-Dividend DateJul 24, 2025
Volumen/a
Average Volume1,073
Open2.124
Previous Close2.024
Day's Range2.090 - 2.146
52-Week Range1.484 - 3.220
Betan/a
RSI55.93
Earnings DateMar 24, 2026

About FRA:08HH

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. manufactures, distributes, and sells pharmaceutical products in Mainland China and internationally. The company offers pharmaceutical products for anti-tumor and immune modulation, metabolism and alimentary system, anti-infection, central nervous system, and cardiovascular system; and APIs and intermediates, including amino acid, tranexamic acid, levamisole hydrochloride, and clindamycin hydrochloride. It also provides mRNA vaccines for Covid-19; medical devices for medical cosmetology respiratory... [Read more]

Industry Pharmaceutical Preparations
Founded 1994
Employees 40,557
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol 08HH

Financial Performance

In 2025, FRA:08HH's revenue was 41.66 billion, an increase of 1.45% compared to the previous year's 41.07 billion. Earnings were 3.37 billion, an increase of 21.69%.

Financial numbers in CNY Financial Statements

News

Generic drugmakers start shipping copies of Takeda's ADHD drug Vyvanse

Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical's drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.

2 years ago - Reuters

Fosun Pharma Shares Gain After Tie-Up With New Covid Drug Supplier Genuine Biotech

Genuine Biotech rec'd China approval on Monday for use of HIV drug in Covid-19 treatment

3 years ago - Forbes

China's health-care sector may be next to face regulatory crackdown, says economist

Dan Wang of Hang Seng Bank (China) says China's public health-care system is still expensive for ordinary people. The country's regulatory reform will be nationwide and have an international impact, s...

4 years ago - CNBC International TV

Fosun Pharma shares tumble more than 5% as Hong Kong suspends BioNTech Covid vaccinations

Shares of Shanghai Fosun Pharmaceutical Group in Hong Kong plunged more than 5% in Wednesday morning trade.

5 years ago - CNBC